13 results
424B5
IKT
Inhibikase Therapeutics Inc
22 May 24
Prospectus supplement for primary offering
8:55am
package for the final pill formulation.
In the ensuing 12 months, the Company anticipates reporting the full outcomes of its completed Phase 1 study
8-K
EX-99.1
IKT
Inhibikase Therapeutics Inc
7 Feb 24
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA
7:59am
with the discussion we had with the FDA as we begin the process of building our first NDA package needed for approval,” said Dr. Milton Werner, President and Chief … from the meeting are subject to formal review of the NDA package. In addition, given that imatinib mesylate is approved for use between 300 mg
424B5
IKT
Inhibikase Therapeutics Inc
1 Feb 24
Prospectus supplement for primary offering
4:49pm
quarter of 2021 and the IND is planned to be filed in the first or second quarter of 2022, to include the production of the data package for the final
424B5
IKT
Inhibikase Therapeutics Inc
16 May 22
Prospectus supplement for primary offering
9:47pm
and an IND is planned to be filed in the second quarter of 2022, to include the production of the data package for the final pill formulation … quarter of 2021 and the IND is planned to be filed in the first or second quarter of 2022, to include the production of the data package for the final pill
S-3
rvr9m
7 Feb 22
Shelf registration
12:00am
8-K
EX-1.1
n1xfs 26d
16 Jun 21
Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock
9:20am
DRS
EX-1.1
om3va
2 Jun 21
Draft registration statement
12:00am
S-1
EX-1.1
7ditam3zd5dtdm zzw
23 Jul 20
IPO registration
12:28pm
- Prev
- 1
- Next